Does BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) Pay a Dividend? (2026)
Last updated July 2026
Short answer
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) pays little or no dividend; like many growth-oriented companies it reinvests cash rather than paying income. A dividend is a slice of profits returned to shareholders, and the yield is that payout divided by the share price, so it drifts as both change. Figures here are approximate; verify the current number with your broker.
Does BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) pay a dividend?
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) currently returns little or nothing as a dividend. BioMarin posted record 2025 revenue of about $3.2 billion and raised its 2026 revenue guidance to roughly $3.83 to $3.93 billion after adding the Amicus products, implying around 20 percent growth at the midpoint. Non-GAAP EPS guidance for 2026 was trimmed slightly to about $4.85 to $5.05 to reflect near-term dilution from the acquisition. Reported trailing GAAP multiples look elevated versus biotech peers, so the story depends on the guided growth materializing.
How to think about BMRN's dividend
- Yield is a snapshot: minimal today, but it moves with price and payout.
- Total return vs income: dividends are one part of return; price change is usually the bigger part for a name like BMRN.
- Reinvest or take income: a DRIP compounds; taking the cash gives income now.
- For more yield: dedicated dividend stocks and ETFs target higher payouts. See the best dividend ETFs.
The bottom line on the BMRN dividend
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) is not an income stock; if you own it, it is for growth or total return, not the dividend. For the full picture see the BMRN guide. Walnut can show how BMRN fits your real portfolio. It is not an investment adviser.
Build a basket around BMRN with Walnut
Use BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Does BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) pay a dividend?
+
BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases (BMRN) pays little or no dividend; like many growth-stage companies it tends to reinvest cash rather than return it as income. Verify the current policy on BMRN's investor relations page.
What is BMRN's dividend yield?
+
BMRN's yield is minimal or zero. Companies prioritizing growth often pay no dividend and return cash through buybacks instead, if at all.
How often does BMRN pay its dividend?
+
US companies that pay dividends, like BioMarin Pharmaceutical develops and sells therapies for rare genetic diseases if it does, typically distribute them quarterly. Confirm the exact schedule and ex-dividend dates on BMRN's investor relations page before relying on the timing.
Can I reinvest BMRN dividends?
+
Yes. Most brokers offer automatic dividend reinvestment (a DRIP) so any BMRN dividend buys more shares automatically. It compounds over time but is still taxable in a taxable account.
Is BMRN a good dividend stock?
+
Walnut is informational, not investment advice. BMRN is a growth or total-return name rather than an income stock. Dedicated dividend stocks and ETFs target higher, steadier yield; match the choice to whether you want income now or growth.
Does BioMarin pay a dividend?
+
BioMarin has historically not paid a dividend, reinvesting cash flow into research, its pipeline and acquisitions such as the Amicus deal. Investors in BMRN have generally been looking for capital appreciation from growth rather than income.
Walnut is informational, not investment advice. Dividend figures are approximate and dated; verify current yield, schedule, and policy with BMRN's investor relations page or your broker.